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ABSTRACT 
 
Prostaglandins (PGs) and thromboxanes (TXs) play a pivotal role in 
cardiovascular physiopathology. They are synthesized from arachidonic acid by the 
enzymatic action of cyclooxygenases (COXs), leading to the production of an unstable 
intermediate, PGH2 that is subsequently converted to the different prostaglandins and 
thromboxanes (PGE2, PGD2, PGI2, PGF2α and TXA2) by the action of different synthases 
and isomerases. There are two well characterized COX enzymes, termed COX-1 and 
COX-2, with different properties. While COX-1 is expressed constitutively in most 
tissues and is thought to be involved in homeostatic prostanoid biosynthesis, COX-2 is 
                                                 
∗ Corresponding author: 
Dr. Manuel Fresno. 
Centro de Biología Molecular Severo Ochoa - Departamento de Biología Molecular. 
Universidad Autónoma de Madrid- Consejo Superior de Investigaciones Científicas. 
Cantoblanco 28049, Madrid, Spain.  
Phone: + 34 911964565; Fax : + 34 911964420; e-mail: mfresno@cbm.uam.es 
Abbreviations: COX, Cyclooxygenase; DP, PGD receptor; EP, PGE receptor; FP, PGF 
receptor; IL, Interleukin; IP, PGI receptor; NSAIDs, non-steroidal anti-inflammatory 
drugs; PG, prostaglandin; PGES, PGE synthase; PGDS, PGD synthase; PGFS, PGF 
synthase; PGIS, PGI synthase; TP, Thromboxane receptor; TX, Thromboxane; TXS, 
Thromboxane synthase. 
M. FRESNO Y COLS.  AN. R. ACAD. NAC. FARM 
 2 
transcriptionally up-regulated in response to mitogens and pro-inflammatory stimuli 
being the predominant isoform involved in the inflammatory response. 
 In the cardiovascular system, prostanoids have been shown to modulate the 
pathogenesis of vascular diseases as thrombosis and atherosclerosis through a variety of 
processes, including platelet aggregation, vasorelaxation and vasoconstriction, local 
inflammatory response and leukocyte-endothelial cell adhesion. Multiple studies using 
pharmacological inhibitors and genetically deficient mice have demonstrated the 
importance of prostanoid-mediated actions on cardiovascular physiology. However, 
recent withdrawal of COX-2 selective inhibitors from the clinic because of their adverse 
effects in patients with potential cardiovascular risk has opened a debate about the role 
of COX–derived prostanoids in vascular pathologies and the benefits and risks for the 
use of COX inhibitors in cardiovascular diseases. 
 
Key words: Prostaglandins.- Thromboxanes.- Cyclooxygenases.- Prostanoid 
receptors.- NSAIDs.- Cardiovascular physiopathology. 
 
 
RESUMEN 
 
Acciones de los prostanoides en la fisiopatología cardiovascular 
 
Las prostaglandinas (PGs) y los tromboxanos (TXs) juegan un papel esencial en 
la fisiopatología cardiovascular. Estos prostanoides son sintetizados a través de la acción 
enzimática de las ciclooxigenasas (COXs) sobre el ácido araquidónico, lo que lleva a la 
producción de un intermediario inestable, la PGH2, a partir de la cual diversas sintetasas 
e isomerasas generarán las diferentes prostaglandinas y tromboxanos (PGE2, PGD2, 
PGI2, PGF2α and TXA2). Existen dos ciclooxigenasas bien caracterizadas denominadas 
COX-1 y COX-2, con diferentes propiedades. COX-1 se expresa constitutivamente en la 
mayoría de los tejidos, estando implicada en la biosíntesis de prostanoides con funciones 
homeostáticas. Por otro lado, la expresión de COX-2 se induce en respuesta a mitógenos 
y estímulos pro-inflamatorios, constituyendo la isoforma predominantemente implicada 
en la respuesta inflamatoria. 
 Los prostanoides modulan la patogénesis de enfermedades vasculares como la 
trombosis y la aterosclerosis a través de una serie de procesos como: la agregación 
plaquetaria, la vasodilatación y vasoconstricción, y la respuesta inflamatoria local. 
Múltiples estudios han demostrado la importancia de las acciones mediadas por los 
prostanoides en la fisiopatología cardiovascular, bien mediante el uso de inhibidores 
farmacológicos o a través del análisis de ratones genéticamente deficientes. Sin 
embargo, la reciente retirada del mercado de inhibidores selectivos de COX-2 a causa de 
sus efectos adversos en pacientes con riesgo cardiovascular, ha abierto el debate sobre el 
papel de los prostanoides en la patología vascular y sobre las ventajas o inconvenientes 
del uso de inhibidores de COXs en las enfermedades cardiovasculares. 
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INTRODUCTION 
 
Prostanoids, including prostaglandins (PGs) and thromboxanes 
(TXs) are a group of bioactive lipids that play a very important role in 
many physiological and pathological processes, including inflammation 
(1), cancer (2), angiogenesis (3) and cardiovascular diseases (4-7). 
Arachidonic acid liberated from membrane phospholipids by several 
phospholipases, is metabolized by the sequential action of 
cyclooxygenases (COX) and prostaglandin or thromboxane synthases to 
produce the diverse classes of prostanoids (8, 9). COX enzymes catalyze 
the formation of an unstable endoperoxide intermediate, PGH2, which in 
turn can be metabolized by cell-specific isomerases and synthases to a 
range of eicosanoids with potent and diverse biological effects, as PGD2, 
PGE2, PGF2α, PGI2, and TXA2 (Figure 1). Finally after their synthesis, 
prostanoids are quickly released to the extracellular medium exerting 
multiple effects upon interaction with prostanoid receptors present in the 
neighbouring cells. 
 
 
CYCLOOXYGENASES 
 
 There are two main COX isoenzymes named COX-1 and COX-2, 
encoded by two separate genes (8-10). A COX-3 enzyme derived from 
alternative splicing of the COX-1 gene has been also described, although 
its role is still unclear (11). COX-1 is constitutively expressed in most, 
but not all, cell types and tissues and is responsible for vascular, renal and 
gastric homeostasis (12). In contrast, COX-2 expression is generally 
induced at sites of inflammation by many stimuli that includes among 
others, proinflammatory cytokines as interleukin (IL)-1β, tumor necrosis 
factor (TNF)-α, growth factors, mechanical stress, oxidized lipids, free 
radicals and bacterial products (9-13). Those stimuli activate many 
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transcription factors such as nuclear factor (NF)-κB, NF-IL6 (C/EBP), 
cAMP response element-binding protein (CREBP), Activator protein 
(AP) -1, interferon regulatory factors (IRFs) and nuclear factor of 
activated T cells (NFAT) (13-15) that induce COX-2 transcription in 
different cell types. COX-2 transcripcional induction can be inhibited by 
anti-inflammatory and immunosuppressive drugs as glucocorticoids and 
Cyclosporin A (16, 17) as well as by anti-inflammatory cytokines such as 
IL-4, IL-10 and IL-13 (18, 19). 
 
 
 
FIGURE 1.- Biosynthesis of prostanoids. Arachidonic acid is liberated from the 
membrane phospholipids by phospholipase A2 (PLA2) and converted to PGH2 and then 
to PGG2 by cyclooxygenases (COX-1 or COX-2). Subsequent conversion of PGH2 to 
different prostanoids (PGs, prostaglandins and TXs, thromboxanes) is catalyzed by the 
respective synthases and isomerases. Prostanoids signal through G protein-coupled 
receptors with seven trans-membrane domains. PGE2 signals via 4 different receptors 
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(EP1, EP2, EP3 and EP4). PGD2, PGF2α, PGI and TXA2 bind to the DP and CRTH2, 
FP, IP and TP receptors respectively. 
 
 Cyclooxygenases are the target of non-steroidal anti-inflammatory 
drugs (NSAIDs). It is generally accepted that these drugs exert their anti-
inflammatory and analgesic actions through inhibition of COX enzymatic 
activity. Classic NSAIDs, such as aspirin, inhibit both isoforms at 
standard doses. Inhibition of COX-1 may account for some of the 
unwanted side effects of these drugs such as gastrointestinal and renal 
toxicity. On the other hand, as COX-2 is though to be the predominant 
isoform involved in the inflammatory response, the ability of NSAIDs to 
inhibit COX-2 activity may explain their therapeutic effects as anti-
inflammatory drugs (Figure 2). Therefore, most of the new research on 
anti-inflammatory drugs has been aimed at targeting the COX-2 inducible 
production of PGs (8, 20). Newly developed drugs with high selectivity 
against COX-2 such as Celecoxib and Rofecoxib have been proved to be 
potent anti-inflammatory compounds without causing gastric toxicity 
(21). 
 Many of the functions associated with each COX isoform have 
been defined by the therapeutic or adverse effects resulting from 
pharmacological inhibition by NSAIDs selective for each isoform. 
However, increasing evidence has shown that certain actions of NSAIDs 
could be mediated through mechanisms independent of cyclooxygenase 
activity and prostaglandin production that may be relevant to their effects 
in vivo (22). Thus, extrapolating the role of COX -derived PGs by the use 
of COX inhibitors may lead to confusing conclusions. In this sense, 
information provided by the use of mice genetically deficient in COX-1 
or COX-2 has provided valuable insight into the roles played by those 
enzymes in vivo (12, 23, 24). These studies have shown that these two 
closely related enzymes have a non-redundant role. Overall, they have 
indicated that, contrary to expectations, both, COX-2 and COX-1 
participate in the maintenance of normal physiology. In this sense, despite 
being mostly inducible, COX-2 deficiency in mice produces dramatic 
phenotypic changes related to normal development and in the 
maintenance of homeostasis. Thus, COX-2 deficiency results in a severe 
defect in renal development and in reproduction in females (25, 26). 
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Surprisingly, COX-1 KO mice show no gastric pathology and are 
resistant to classical NSAIDs-induced gastric ulceration. COX-1 deficient 
mice show reduced platelet aggregation that is consistent with the fact 
that platelets express only COX-1. However, those mice also have a 
decreased arachidonic acid-induced inflammation indicating a role of this 
enzyme in inflammatory responses (27). 
 
 
 
 
FIGURE 2.- Cyclooxygenases are the target of non-steroidal anti-inflammatory drugs 
(NSAIDs). NSAIDs exert their anti-inflammatory and analgesic actions through 
inhibition of COX enzymatic activity. Classical non selective NSAIDs, such as Aspirin 
and Indomethacin inhibit COX-1 and COX-2 isoforms at standard doses. Unwanted side 
effects of these drugs such as gastrointestinal and renal toxicity occurs through the 
inhibition of the COX-1 –dependent production of prostanoids involved in physiological 
functions. The ability of NSAIDs to inhibit COX-2 activity explains their therapeutic 
effects as anti-inflammatory drugs. Newer NSAIDs belonging to the family of Coxibs, 
such as Celecoxib and Rofecoxib, with high selectivity against COX-2, have been shown 
to exhibit potent anti-inflammatory properties without causing gastric toxicity. 
 
 
 Subcellular location of COX isoenzymes may also be important in 
determining their distinct functions. Thus, COX-1 has been mainly 
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located in the endoplasmic reticulum and nuclear envelope whereas COX-
2 is preferentially expressed around the nuclear membrane (9, 12). 
 
 
PROSTAGLANDIN AND THROMBOXANE SYNTHASES 
 
 Despite the importance of COX isoenzymes in prostanoid 
generation, the actual prostanoid profile synthesized by a particular cell 
type is determined by the presence of different downstream PG and TX 
synthases and isomerases (28) (Figure 1). A particular cell type may 
predominantly express a particular isomerase, which will largely 
determine which prostanoid is generated. Moreover, some cell types can 
express more than one isomerase and a particular COX isoenzyme can 
couple to different isomerases in the same cell (29). Thus, COX-1 
preferentially couples with Thromboxane synthase (TXS) and PGF2α 
synthase (PGFS), while COX-2 is associated to Prostacyclin synthase 
(PGIS) and microsomal PGE2 synthase -1 (mPGES-1) (29, 30). 
Evenmore, PGH2 and other endoperoxides generated in one cell type may 
be secreted and metabolized by isomerases present in surrounding cells 
by the so-called “transcellular metabolism” (31). 
 PGE2 is synthesized by the action of PGE synthases (PGES) of 
which there are 3 types: one cytosolic (cPGES) and two membrane-
associated PGE synthases (mPGES)-1 and -2. The (cPGES) belongs to 
the glutathione transferase family, is ubiquitously expressed and is 
preferentially functionally coupled to COX-1, thus, involved in 
housekeeping production of PGE2 (32, 33). In contrast, mPGES-1, which 
belongs to the Membrane-Associated Proteins involved in Eicosanoid and 
Glutathione metabolism (MAPEG) superfamily, is inducible by similar 
stimuli that induce COX-2, being its induction also suppressed by 
glucocorticoids. Moreover, mPGES-1 appears functionally coupled with 
COX-2 and its induction is usually coordinated with COX-2 (34). A 
second type of membrane-bound microsomal PGES is the mPGES-2, able 
to couple with both COX isoenzymes, although its functional significance 
is still unclear (35). 
PGD2 is synthesized from PGH2 by the action of PGD synthases 
(PGDS) of which there are two isoforms. The haematopoietic PGDS is 
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present in mast cells, basophils, and in a subset of T helper cells (Th2) 
and may play a role in allergy (36). The lipocalin–type PGD synthase is 
mostly expressed in brain and it is especially abundant in the 
cerebrospinal fluid (37). Interestingly, PGD2 can be further metabolized 
by dehydration to PGJ2, delta12-PGJ2, and 15- deoxy-delta(12,14)-PGJ2, 
which is a ligand for the nuclear transcription factor peroxisomal 
proliferator activated receptor (PPAR)-gamma having anti-inflammatory 
activity (38). 
PGF2α can be synthesized from PGH2 by PGH 9-11-endoperoxide 
reductase or PGF synthase (PGFS). In addition it can be generated from 
PGE2 by PGE 9-ketoreductase or from PGD2 by PGD-11-ketoreductase 
(39). 
Prostacyclin, PGI2, is produced by the action of PGI synthase 
(PGIS) which can be induced by mechanical stress, via activation of AP-1 
(40). 
TXA2 is synthesized from PGH2 by thromboxane synthase (TXS), 
which is constitutively expressed in platelets as well as other blood cells 
and various tissues as kidney, lung, liver and placenta. Its regulation takes 
place mainly at the transcriptional level (41). 
 
 
PROSTANOID RECEPTORS 
 
 Prostanoids actions, with the possible exception of cyclopentenone 
PGs, are mediated through cell surface receptors. These are cell seven 
membrane spanning G-protein coupled receptors that are classified into 
five basic types, named according to their ligands: DP for PGD2, EP for 
PGE2, FP for PGF2, IP for PGI2, and TP for TXA2 (6, 42). 
DP (also named DP1) is weakly expressed in brain despite the 
important action of PGD2 in this organ. It is moderately expressed in the 
ileum with very weak expression in the lung. DP2, also called CRTH2 
(chemoattractant receptor-homologous molecule expressed on Th2 cells), 
is expressed on Th2 immune cells being a chemoattractant receptor for 
Th2 lymphocyte subset in allergic inflammation (43). 
FP is most abundantly expressed in the corpus luteum according to 
the role played by PGF2α in menstrual cycle. It is also expressed in the 
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heart, lung, kidney, and stomach, although its expression in these tissues 
does not vary during the estrous cycle as does in the corpus luteum (44). 
There are several splice variants of FP (FPA and FPB) but its particular 
role is unclear. 
IP is expressed in larger quantities by dorsal root ganglion neurons 
but also by platelet precursors (megakaryocytes) as well as in the smooth 
muscle cells of arteries consistent with the important action of PGI2 in the 
cardiovascular system (45). 
PGE2 has four receptors, EP1 to 4. In addition, there are several 
splice variants of EP3. More importantly, each one is linked to a different 
transduction pathway that may even give rise to opposite effects 
(activation or inhibition) on cellular responses (6). Thus, EP1 induces an 
inhibition of adenylate cyclase leading to a decrease in cAMP whereas 
EP2 and EP4 receptors activate this enzyme. On the other hand, EP3 is 
coupled to Gαq and its activation results in intracellular calcium increase. 
EP3 and EP4 receptors have a wide distribution throughout the body, 
being expressed in almost all tissues examined. In contrast, of EP1 is 
restricted to the lung, kidney and stomach, and EP2 is scarcely expressed. 
In the cardiovascular system, IP, DP, EP4 and EP2 receptors that 
mediate cAMP increases are termed “relaxant” receptors, whereas TP, 
FP, and EP1 receptors, which induce calcium mobilization, represent the 
“contractile” receptor group. EP3, which reduces cAMP levels, has been 
named the “inhibitory” receptor (6). 
Nuclear actions of prostanoids have also been reported. Thus, 
PGJ2 derivatives can bind and activate peroxisome proliferator-activated 
receptors (PPARs) nuclear transcription factors (46). There are four types 
of PPARs (alpha, delta, gamma-1, and gamma-2), which may bind 
various PGs with different sensitivity (47). In this way, PGs may also act 
as intracellular signalling molecules and regulate gene expression (48). 
Generally PPARs induces transcription of anti-inflammatory genes as 
well as inhibits activation of pro-inflammatory ones (46). Besides, 
cyclopentenone PGs (that includes PGA1) have a reactive ring which may 
lead to have receptor-independent actions through redox alterations (49). 
 
 
PROSTANOIDS IN CARDIOVASCULAR HOMEOSTASIS 
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 Among eicosanoids, TXA2 and PGI2 are thought to be the most 
important prostanoids in controlling the homeostasis of the cardiovascular 
system, as proposed more than 20 years ago by Bunting, Moncada and 
Vane (5, 50, 51). They are synthesized by blood platelets and vascular 
endothelium, respectively, and have opposed biological activities. TXA2 
is potent vasoconstrictor as well as a potent inducer of platelet adhesion 
and regulates renal hemodynamics and sodium handling by the kidney 
(4). On the other hand, PGI2 is the predominant prostanoid produced by 
cells of the vasculature, having an important vasodilator effect by 
promoting renal sodium excretion and regulating the growth of vascular 
smooth muscle cells. Moreover, it opposes TXA2 effects on platelets 
inhibiting their aggregation and action (28, 52). 
Due to this, many aspects of cardiovascular disease have 
traditionally been explained by alterations in the balance between PGI2 
and TXA2 during the interactions between platelets and vessel wall (53) 
although recent studies argue about this theory (54). Since platelets 
express COX-1 but not COX-2, it is inferred that TXA2 production by 
TXAS uses PGH2 derived from COX-1. In this regard, platelet TXA2 is 
blunted in COX-1 deficient mice, which have decreased platelet 
aggregation and thrombosis (55). Mice deficient in the TP (51, 56) or 
human patients with a genetic disorder in the TP receptor (57, 58) exhibit 
an increase in bleeding tendency and resistance to platelet aggregation, 
confirming the role of TXA2 in those activities and consistent with the 
effects of TP antagonists in humans. Conversely, transgenic mice 
specifically overexpressing TP in the vasculature results in placental 
ischemia during pregnancy and suppression of TXA2 formation rescue the 
phenotype (59). Since TXA2 is a mitogen of vascular smooth muscle 
cells, TP KO mice have decreased vascular proliferation and platelet 
response after artery injury to the carotid although they are normotensive 
(51). 
 Whether PGI2 is synthesized through COX-1 or COX-2 has been 
of paramount importance in classical cardiovascular research. Initial 
reports indicated that vascular endothelial cells and smooth muscle cells 
have COX-1, and that PGI2 can be formed through COX-1 which was 
supported by the fact that in endothelial cells, PGIS co-localizes with 
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COX-1 but not with COX-2 (10, 54). However, PGIS expression can be 
induced together with COX-2 in endothelial cells by hemodynamic shear 
stress or by oxidized low density lipoproteins (oxLDLs) leading to PGI2 
production (60, 61). Moreover, in healthy individuals COX-2 specific 
inhibitors reduce PGI2 metabolites in urine without affecting TXA2 
metabolites (62). This suggests that COX-2 is a major source of PGI2 in 
the human cardiovascular system and plays a role under physiological 
conditions. The predominant coupling of PGI2 to COX-2 suggests that 
COX-2 specific inhibitor could be prothrombotic, since anti-aggregatory 
PGI2 circulating levels within would be reduced. This has been proposed 
to explain the putative associations between COX-2 inhibitors and the 
development of cardiovascular complications (63, 64). In contrast to TP 
deficient mice, IP knockout mice have normal blood pressure and develop 
normally without suffering from spontaneous thrombosis. However, after 
endothelial damage they show an enhanced thrombotic response 
compared to control littermates (65), indicating that PGI2 does play a 
major role only in response to stress and not in the basal systemic 
circulation. Mice lacking IP have enhanced vascular smooth cell 
proliferation and platelet activation in response to vascular injury likely 
caused by enhanced TXA2/PGI2 ratio (51). Simultaneous deletion of the 
TP and the IP abrogated both increased responses (51). Selective 
inhibition, knockout, mutation or deletion of COX-2 or IP has been 
shown to accelerate thrombogenesis. These responses were attenuated by 
COX-1 knock down (66). IP KO mice also show vascular hyperplasia and 
increased vascular remodeling (67) as well as cardiac hypertrophy and 
fibrosis (68). Taken together those results indicate that PGI2 regulates the 
cardiovascular activity of TXA2 and further support the hypothesis that 
cardiovascular homeostasis is resulting from the balance between these 
two eicosanoids.  
 
 
ROLE OF PROSTANOIDS IN ATHEROSCLEROSIS 
 
 Atherosclerosis is one of the most important diseases of the 
developed countries and can be considered as a multifactorial 
inflammatory disease triggered by high levels of cholesterol in serum 
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leading to an inflammation in the intima of large arteries and involving 
several cell types including immune cells as T lymphocytes and 
monocytes/macrophages as well as endothelial and smooth muscle cells 
and platelets (69, 70). Among those, monocytes/macrophages play an 
important key role in many phases of atherogenic process. Thus, after an 
atherogenic stimulus, monocyte-macrophages reversibly adhere to the 
endothelium and migrate across it, leading to a prolonged retention of 
those cells in the intima which is central in atherogenesis. A variety of 
substances including prostanoids have been implicated in the 
pathogenesis of atherosclerosis. 
 Prostanoids may be involved in atherosclerosis through their 
ability to regulate a variety of mechanisms potentially involved in the 
pathogenesis such as inflammation, vasodilatation, vasoconstriction, 
platelet aggregation and leukocyte–endothelial cell adhesion, and 
leukocyte migration among others (71, 72). In this regard, COX-2 
expression has been observed in symptomatic atherosclerotic lesions (73). 
This enzyme may play a dual role in the pathogenesis of the 
atherosclerosis. Initially, COX-2 expression is induced in monocytes by 
pro-inflammatory cytokines and several growth factors. Then, COX-2-
mediated PG production by activated macrophages may promote 
atherosclerosis in the artery wall through several mechanisms, as 
induction of other proinflammatory mediators or by favouring migration 
of macrophages and other immune cells or by induction of adhesion 
molecules. Later on, COX-2-derived PGI2, likely from the endothelial 
cells, may have a protective role in atherogenesis by favouring 
vasodilatation. Moreover, in atherosclerotic patients, PGI2 can be formed 
through the action of both COX-1 and COX-2 (54). COX-1 but not COX-
2 is expressed in normal arteries, whereas both isoforms are expressed in 
atherosclerotic lesions. In those lesions COX-2 is expressed not only by 
monocyte/macrophages, but also by endothelial and proliferating smooth 
muscle cells (7). Atherogenic lipoproteins, such as oxidized low density 
lipoproteins (oxLDL) may promote atherosclerosis first by contributing to 
inflammation by activating monocytes/macrophages and later by 
stimulating lipid uptake by macrophages, leading to foam cell formation. 
Interestingly, oxLDL has apparently contradictory effect on macrophages, 
since they can activate the expression of some pro-inflammatory genes 
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whereas reduce COX-2 expression (74). In agreement with this is the fact 
that macrophage-derived foam cells from the atherosclerotic lesions in 
mice, did not express COX-2. Thus induction COX-2 expression in 
macrophages takes place before their transformation into foam cells in the 
plaques. 
 In spite of the clear involvement of COX-2 derived prostanoids in 
vascular atherosclerosis, results on the effect of COX-2 selective 
inhibitors on the formation and progression of atherosclerotic plaques are 
controversial. Results from different studies have shown increased, 
reduced as well as unaltered atherogenesis (7, 62, 75-78). Those 
discrepant effects of COX-2 may reflect the dual role of COX-2 in 
promoting (early) but protecting later atherosclerotic lesions, mentioned 
above. Results about the influence of COXs in atherosclerosis in animal 
models, apart from those using pharmacological inhibitors, have been 
obtained by means of cell transplantation from fetal liver or bone marrow 
from COX-1 or COX- 2 deficient mice into ApoE or LDLR KO mice (75, 
79, 80). The size of the atherosclerotic lesions was significantly reduced 
when cells deficient in COX-2 were transplanted compared to the mice 
transplanted with wild type fetal liver cells (75, 80). Those results 
implicate COX-2 expression in the macrophage and not in other cells as 
endothelial cells, smooth muscle cells, or T-cells in promoting 
atherosclerotic lesion formation. Efforts to obtain information from mice 
deficient in both COX-2 and ApoE or LDLR genes have been 
unsuccessful due to the severe renal defects of COX-2 mice. Regarding to 
COX-1, both proatherosclerotic and anti-atherosclerotic roles also have 
been reported (79, 81). 
 Various prostanoids may play a significant role in the atherogenic 
process (71, 82). Patients with extensive disease as well as murine models 
of atherosclerosis have enhanced formation of TXA2. Even more, TP 
antagonists decrease atherogenesis in mice. TP deficiency in 
atherosclerotic mice models induced a significant delay in atherogenesis, 
compared with mice deficient in apoE alone (72). 
 In contrast, PGI2 may theoretically have a beneficial effect in the 
atherogenic process by limiting platelet adhesion to the endothelium and 
activation in the plaques. In accordance with this, local delivery of PIGS 
gene through an adenoviral vector reduces the platelet deposition seen 
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following vascular injury (83). Genetic deletion of the IP receptor, both in 
the LDRL and in the ApoE KO mice models, aggravated atherogenesis 
(72, 84). As platelets are though to contribute to the development and 
progression of atherosclerosis in the late phase, PGI2 may likely suppress 
lesion formation by limiting platelet deposition. Those mice exhibited a 
significant acceleration in atherogenesis with enhanced platelet activation 
and increased rolling of leukocytes on the vessel walls. Those results 
indicate that TXA2 promotes whereas PGI2 prevents the initiation and 
progression of atherogenesis by modulating platelet activation and 
leukocyte-endothelial cell interaction. 
In addition to PGI2 and TXA2, other PGs, such as PGE2 and PGD2, 
could also play an important role in the pathophysiology of 
atherosclerosis. In this regard, vasoconstrictor responses to PGE2 are 
greatly increased in atherosclerosis (85) and PGE2 may also promote 
angiogenesis (3). Moreover, inducible mPGES-1 has been detected in 
activated macrophages in atherosclerotic lesions where it colocalizes with 
COX-2 both in mice and humans (73). Disruption of this enzyme in mice 
reduced foam cell formation and atherosclerosis in fat-fed LDLR-/- mice. 
mPGES-1 deletion augmented both PGIS and TXS expression in 
endothelial cells (86). On the other hand, COX-2 derived PGs as PGD2 
may possess anti-inflammatory and anti-atherosclerotic properties in such 
a way that the balance between PGDS and PGES has been shown to be a 
major determinant of atherosclerotic plaque instability (87). 
 
 
PHARMACOLOGICAL IMPLICATIONS 
 
 Based on the hypothesis that atherosclerosis is an inflammatory 
disease, it was proposed that COX inhibition by NSAIDs, and in 
particular selective inhibition of COX-2 by the Coxibs family of NSAIDs, 
might have protective and even anti-atherogenic effects. However, 
clinical studies have indicated that there is an increased risk of 
atherothrombosis in individuals taking these drugs in such a way that 
some of them as Rofecoxib have been recently withdrawn from the 
market (88-91). These undesirable effects of COX-2 selective inhibitors 
have been explained by the TXA2/PGI2 balance theory by which selective 
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inhibition of COX-2 lead to a reduction in the production of the 
vasodilator PGI2 whereas production of the vasoconstrictor and pro-
aggregatory TXA2, mostly COX-1–dependent, remains unaffected. Thus, 
disruption of the physiological balance between TXA2 and PGI2 
accelerates atherosclerosis and increases the risk of thrombosis and other 
cardiovascular complications (Figure 3). 
 
 
 
FIGURE 3.- The balance hypothesis for the cardiovascular effects of NSAIDs. 
Cardiovascular homeostasis is controlled by the balance between COX-1 –dependent 
production of TXA2 by platelets and COX-2 –mediated PGI2 (prostacyclin) production 
by endothelial cells. Whereas TXA2 function as a potent platelet activator and 
vasoconstrictor, PGI2 inhibits platelet aggregation and thrombosis. Classical non-
selective NSAIDs reduce the production of TXA2 by platelets through their ability to 
inhibit COX-1 activity thus displaying anti-thrombotic properties. In contrast, COX-2 
selective NSAIDs reduce PGI2 formation by endothelial cells consequently disturbing the 
equilibrium between TXA2 and PGI2 and potentially favouring pro-thrombotic 
cardiovascular events. 
 
 
 Nevertheless, the mechanisms underlying the pathogenesis of 
cardiovascular complications upon NSAIDs administration remain to be 
clarified as the TXA2/PGI2 balance theory is somewhat simple and it does 
not consider some important clinical and experimental evidences as the 
increased risk of cardiovascular events by some non-selective NSAIDs, 
the contribution of other prostanoids to the overall effect in 
cardiovascular physiopathology, and the COX-2 independent effects of 
NSAIDs. In this sense, a more profound knowledge of the complex 
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relations between prostanoids-mediated actions and function of cells in 
the cardiovascular system is required to clearly understand the benefits 
and risks of NSAIDs on cardiovascular diseases. 
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